INM Stock Catalyst: InMed Pharmaceuticals Announces Preclinical Success of INM-901 in Reducing Alzheimer's-Related Inflammation

Jan 21, 2025 · 7:31am ET

Company reports statistically significant reductions in key neurodegeneration and neuroinflammatory markers.

Max move

+91.4%

High of day $9.17

Sparker timei

7:31am ET

INM · Jan 21, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

InMed Pharmaceuticals Inc. (XNAS: INM) announced that its drug candidate INM-901 demonstrated a reduction in Alzheimer's-related inflammation and achieved statistically significant reductions in the neurodegeneration marker Neurofilament Light Chain and neuroinflammatory genes in a preclinical study.

The study results showed a marked decrease in both the Neurofilament Light Chain and several neuroinflammatory genes, indicating the potential therapeutic benefits of INM-901 in treating Alzheimer's disease. The company did not provide specific numerical data on the reductions observed.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time INM sparks.

Download Sniper App →

Catch the next INM-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →